Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
Abstract Objective The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. Methods Total of 40 patients were enrolled in the study between September 2019 and...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6602 |
| _version_ | 1797626726466977792 |
|---|---|
| author | Zhenyu Wen Junxiao Wang Bo Tu Yane Liu Yuqing Yang Li Hou Xiang Yang Xiaoyan Liu Hui Xie |
| author_facet | Zhenyu Wen Junxiao Wang Bo Tu Yane Liu Yuqing Yang Li Hou Xiang Yang Xiaoyan Liu Hui Xie |
| author_sort | Zhenyu Wen |
| collection | DOAJ |
| description | Abstract Objective The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. Methods Total of 40 patients were enrolled in the study between September 2019 and November 2021. Data follow‐up ends in April 2022. The study’s main focus is on recurrence free survival (RFS), while the secondary objectives was safety. Chi‐square tests, Kaplan‐Meier, and Cox proportional hazards models were utilized to analyze the data. Results The median follow‐up period was 21.40 months, and the median RFS was 15.40 months in the group that received combination therapy, which was statistically significantly different (HR: 0.44, p = 0.04) compared with the RFA group (8.2 months). RFS rates (RFSr) at 6, 12 and 18 months in the combination therapy groups and RFA groups were 80% vs 65%, 62.7% vs 35% and 48.7% vs 18.8%, respectively. Between the two groups, significant difference of RFSr was found at 18 months (p = 0.04). No statistical differences were observed between the two groups in terms of safeness (p > 0.05). The subgroup analysis indicated that the combination of RFA and anti‐PD‐1 led to better RFS than RFA alone. Moreover, patients benefited more from combination therapy in the groups younger than 60 years (HR: 0.26, p = 0.018), male (HR: 0.32, p = 0.028) and Child‐Pugh grade A (HR: 0.38, p = 0.032). Conclusions Combining RFA with anti‐PD‐1 showed improved RFS and was deemed safe for patients with recurrent HCC who had previously undergone RFA treatment alone. |
| first_indexed | 2024-03-11T10:14:17Z |
| format | Article |
| id | doaj.art-ebf45b46a35b48c7bd644f29d77efbc3 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-11T10:14:17Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-ebf45b46a35b48c7bd644f29d77efbc32023-11-16T12:08:59ZengWileyCancer Medicine2045-76342023-10-011220203112032010.1002/cam4.6602Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trialZhenyu Wen0Junxiao Wang1Bo Tu2Yane Liu3Yuqing Yang4Li Hou5Xiang Yang6Xiaoyan Liu7Hui Xie8Department of Public Health Jilin University Jilin ChinaAerospace Medical Center Aerospace Center Hospital Beijing ChinaDepartment of Infectious Diseases Fifth Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Public Health Jilin University Jilin ChinaDepartment of Public Health Jilin University Jilin ChinaDepartment of Oncology Fifth Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Oncology Fifth Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Hepatology Fifth Medical Center of Chinese PLA General Hospital Beijing ChinaDepartment of Oncology Fifth Medical Center of Chinese PLA General Hospital Beijing ChinaAbstract Objective The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. Methods Total of 40 patients were enrolled in the study between September 2019 and November 2021. Data follow‐up ends in April 2022. The study’s main focus is on recurrence free survival (RFS), while the secondary objectives was safety. Chi‐square tests, Kaplan‐Meier, and Cox proportional hazards models were utilized to analyze the data. Results The median follow‐up period was 21.40 months, and the median RFS was 15.40 months in the group that received combination therapy, which was statistically significantly different (HR: 0.44, p = 0.04) compared with the RFA group (8.2 months). RFS rates (RFSr) at 6, 12 and 18 months in the combination therapy groups and RFA groups were 80% vs 65%, 62.7% vs 35% and 48.7% vs 18.8%, respectively. Between the two groups, significant difference of RFSr was found at 18 months (p = 0.04). No statistical differences were observed between the two groups in terms of safeness (p > 0.05). The subgroup analysis indicated that the combination of RFA and anti‐PD‐1 led to better RFS than RFA alone. Moreover, patients benefited more from combination therapy in the groups younger than 60 years (HR: 0.26, p = 0.018), male (HR: 0.32, p = 0.028) and Child‐Pugh grade A (HR: 0.38, p = 0.032). Conclusions Combining RFA with anti‐PD‐1 showed improved RFS and was deemed safe for patients with recurrent HCC who had previously undergone RFA treatment alone.https://doi.org/10.1002/cam4.6602anti‐PD‐1prospective studyradiofrequency ablationrecurrent hepatocellular carcinomatoripalimab |
| spellingShingle | Zhenyu Wen Junxiao Wang Bo Tu Yane Liu Yuqing Yang Li Hou Xiang Yang Xiaoyan Liu Hui Xie Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial Cancer Medicine anti‐PD‐1 prospective study radiofrequency ablation recurrent hepatocellular carcinoma toripalimab |
| title | Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial |
| title_full | Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial |
| title_fullStr | Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial |
| title_full_unstemmed | Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial |
| title_short | Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial |
| title_sort | radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma a prospective controlled trial |
| topic | anti‐PD‐1 prospective study radiofrequency ablation recurrent hepatocellular carcinoma toripalimab |
| url | https://doi.org/10.1002/cam4.6602 |
| work_keys_str_mv | AT zhenyuwen radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT junxiaowang radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT botu radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT yaneliu radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT yuqingyang radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT lihou radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT xiangyang radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT xiaoyanliu radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial AT huixie radiofrequencyablationcombinedwithtoripalimabforrecurrenthepatocellularcarcinomaaprospectivecontrolledtrial |